Trends in Cardiovascular Medicine
Volume 15, Issue 7 , Pages 243-249 , October 2005

Are Suppressors of Cytokine Signaling Proteins Recently Identified in Atherosclerosis Possible Therapeutic Targets?

  • Jingjing Tang
    • ,
  • Elaine W. Raines

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Elaine W. Raines, Harborview Medical Center, 325 9th Ave, Box 359675, Seattle, WA 98104-2499, USA. Tel.: (+1) 206-341-5410; fax: (+1) 206-341-5416.

References 

  1. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol. 2004;22:503–529
  2. Alexander WS, Starr R, Fenner JE, et al. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 1999;98:597–608
  3. Binder CJ, Chang MK, Shaw PX, et al. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8:1218–1226
  4. Bjorkbacka H, Kunjathoor VV, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004;10:416–421
  5. Bjorbaek C, Lavery HJ, Bates SH, et al. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem. 2000;275:40649–40657
  6. Boring L, Gosling J, Chensue SW, et al. Impaired monocyte migration and reduced type 1 (TH1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest. 1997;100:2552–2561
  7. Chen Y, Chong MM, Darwiche R, et al. Severe pancreatitis with exocrine destruction and increased islet neogenesis in mice with suppressor of cytokine signaling-1 deficiency. Am J Pathol. 2004;165:913–921
  8. Chong MM, Cornish AL, Darwiche R, et al. Suppressor of cytokine signaling-1 is a critical regulator of interleukin-7-dependent CD8+ T cell differentiation. Immunity. 2003;18:475–487
  9. Chong MM, Metcalf D, Jamieson E, et al. Suppressor of cytokine signaling-1 in T cells and macrophages is critical for preventing lethal inflammation. Blood. 2005;[e-published May 15, 2005]
  10. Croker BA, Krebs DL, Zhang JG, et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol. 2003;4:540–545
  11. Egan PJ, Lawlor KE, Alexander WS, et al. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J Clin Invest. 2003;111:915–924
  12. Elliott J, Johnston JA. SOCS: role in inflammation, allergy and homeostasis. Trends Immunol. 2004;25:434–440
  13. Federici M, Giustizieri ML, Scarponi C, et al. Impaired IFN-gamma-dependent inflammatory responses in human keratinocytes overexpressing the suppressor of cytokine signaling 1. J Immunol. 2002;169:434–442
  14. Frostegard J, Ulfgren A, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (TH1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33–43
  15. Fujimoto M, Tsutsui H, Xinshou O, et al. Inadequate induction of suppressor of cytokine signaling-1 causes systemic autoimmune diseases. Int Immunol. 2004;16:303–314
  16. Gosling J, Slaymaker S, Gu L, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest. 1999;103:773–778
  17. Hansson GK, Libby P, Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281–291
  18. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685–1695
  19. Huang K, Chen C, Chen J, et al. Statins induce suppressor of cytokine signaling-3 in macrophages. FEBS Lett. 2003;555:385–389
  20. Ilangumaran S, Ramanathan S, Rottapel R. Regulation of the immune system by SOCS family adaptor proteins. Semin Immunol. 2004;16:351–365
  21. Inoue H, Kubo M. SOCS proteins in T helper cell differentiation: implications for allergic disorders?. Expert Rev Mol Med. 2004;6:1–11
  22. Kwak B, Mulhaupt F, Myit S, et al. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399–1402
  23. Laurat E, Poirier B, Tupin E, et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 2001;104:197–202
  24. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–874
  25. Lutgens E, Cleutjens K, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A. 2000;97:7464–7469
  26. Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313–1316
  27. Marine JC, McKay C, Wang D, et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell. 1999;98:617–627
  28. Michelsen KS, Wong MH, Shah PK, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A. 2004;101:10679–10684
  29. Naka T, Matsumoto T, Narazaki M, et al. Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci U S A. 1998;95:15577–15582
  30. Pinderski L, Fischbein M, Subbanagounder G, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res. 2002;90:1064–10671
  31. Rajavashisth T, Qiao J, Tripathi S, et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 1998;101:2702–2710
  32. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  33. Seki Y, Inoue H, Nagata N, et al. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med. 2003;9:1047–1054
  34. Shouda T, Yoshida T, Hanada T, et al. Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest. 2001;108:1781–1788
  35. Starr R, Metcalf D, Elefanty AG, et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling-1. Proc Natl Acad Sci U S A. 1998;95:14395–14399
  36. Suzuki A, Hanada T, Mitsuyama K, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med. 2001;193:471–481
  37. Tang J, Kozaki K, Farr A, et al. The absence of PDGF-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE−/− mice. Am J Pathol. 2005;167:901–912
  38. Ueki K, Kondo T, Kahn CR. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol. 2004;24:5434–5446
  39. Wesemann DR, Dong Y, O'Keefe H, et al. Suppressor of cytokine signaling 1 inhibits cytokine induction of CD40 expression in macrophages. J Immunol. 2002;169:2354–2360
  40. Yasukawa H, Ohishi M, Mori H, et al. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol. 2003;4:551–556
  41. Yoshimura A, Ohishi HM, Aki D, et al. Regulation of TLR signaling and inflammation by SOCS family proteins. J Leukoc Biol. 2004;75:422–427
  42. Yoshimura A, Nishinakamura H, Matsumura Y, et al. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther. 2005;7(3):100–110[2005 Mar 30]
  43. Zhou X, Paulsson G, Stemme S, et al. Hypercholesterolemia is associated with a T helper (Th) 1/TH2 switch of the autoimmune response in atherosclerotic ApoE-knockout mice. J Clin Invest. 1998;101:1717–1725

PII: S1050-1738(05)00126-X

doi: 10.1016/j.tcm.2005.08.001

Trends in Cardiovascular Medicine
Volume 15, Issue 7 , Pages 243-249 , October 2005

Article Tools

* Image Usage & Resolution